SCHEMBL28627110

SCHEMBL28627110

CCCCCCON(C(=O)[C@H]([C@@H](C)CC)[C@@H]1CCCCN1C)[C@H](C[C@@H](O[Si](C)(C)C(C)(C)C)c1nc(C(=O)OCC)cs1)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.33
CTSK P43235 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22154622 0.88 FAP (0.37) ABCB1CTSKSMN1; SMN2
SCHEMBL28629632 0.87 FAP (0.36) ABCB1CTSKSMN1; SMN2
SCHEMBL22154694 0.83 ABCB1 (0.36) ABCB1
SCHEMBL24140426 0.81 POLB (0.38) ABCB1SMN1; SMN2
SCHEMBL28632004 0.81 ABCB1 (0.34) ABCB1
SCHEMBL28632005 0.81 ABCB1 (0.34) ABCB1
SCHEMBL28629473 0.80 FAP (0.35) ABCB1SMN1; SMN2
SCHEMBL28631046 0.80 ABCB1 (0.43) ABCB1
SCHEMBL28631048 0.80 ABCB1 (0.43) ABCB1
SCHEMBL24140272 0.79 FAP (0.41) ABCB1CTSKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12144864-B2 Tubulysins and protein-tubulysin conjugates REGENERON PHARMACEUTICALS, INC. (US) 2024-11-19 US disclosed
CN-113454097-A Tubulysins and protein-tubulysin conjugates 里珍纳龙药品有限公司 2021-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12144864-B2 Tubulysins and protein-tubulysin conjugates SDCBP, TEK, TEKT1 ABCB1 895/4885CTSK 1735/4885SMN1; SMN2 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.